Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients :
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients UNIVERSITY OF STUDIES MESSINA SCHOOL OF MEDICINE AND SURGERY DEPARTMENT OF SURGERY, ONCOLOGY AND PATHOLOGY TARGET DISEASES PSEUDOMYXOMA PERITONEAL (APPENDIX MUCINOUS CARCINOMAS) Peritoneal mesothelioma RETROPERITONEAL SARCOMA AND SARCOMATOUS OVARIAN CANCER PERITONEAL CARCINOMATOSIS FROM COLORECTAL CANCER PERITONEAL CARCINOMATOSIS FROM STOMACH CANCER ANTONIO MACRÌ, EDOARDO SALADINO, GIUSEPPE TRIMARCHI, VINCENZO BARTOLO, MAURIZIO ROSSITTO, ANTONIO CANNAÒ, ANTONGIACOMO RIZZO, and CIRO FAMULARI
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients Vivo July-August 2011 25 (4) 687-690:
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients Vivo July-August 2011 25 (4) 687-690 UNIVERSITY OF STUDIES MESSINA SCHOOL OF MEDICINE AND SURGERY DEPARTMENT OF SURGERY, ONCOLOGY AND PATHOLOGY ANTONIO MACRÌ, EDOARDO SALADINO, GIUSEPPE TRIMARCHI, VINCENZO BARTOLO, MAURIZIO ROSSITTO, ANTONIO CANNAÒ, ANTONGIACOMO RIZZO, and CIRO FAMULARI Abstract Background: The treatment of peritoneal malignancies in elderly patients with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is an ongoing question due to the high associated surgical risk. Patients and Methods: Thirty patients, 11 (36.7%) older than 65 years, were submitted to CRS plus HIPEC. Criteria of patient eligibility were: peritoneal carcinomatosis of different origin, T3-4 gastric cancer, ECOG performance status ≤2, no extra-abdominal extension and no evidence of bowel obstruction. The median follow-up was 21.5 months (range: 1-63). The purpose of this retrospective study, was to evaluate the feasibility of this approach in elderly patients, with special reference to postoperative morbidity, mortality and survival. Results: We have recorded, in elderly patients, higher grade 3 and 4 morbidity and mortality, similar mean duration of cytoreductive surgery, of postoperative hospital stay, of median survival and of overall survival rates. Conclusion: Since there no statistical differences, in terms of morbidity and mortality, CRS with HIPEC may also be suitable for elderly patients.
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients Vivo July-August 2011 25 (4) 687-690:
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients Vivo July-August 2011 25 (4) 687-690 UNIVERSITY OF STUDIES MESSINA SCHOOL OF MEDICINE AND SURGERY DEPARTMENT OF SURGERY, ONCOLOGY AND PATHOLOGY ANTONIO MACRÌ, EDOARDO SALADINO, GIUSEPPE TRIMARCHI, VINCENZO BARTOLO, MAURIZIO ROSSITTO, ANTONIO CANNAÒ, ANTONGIACOMO RIZZO, and CIRO FAMULARI
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients Vivo July-August 2011 25 (4) 687-690:
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients Vivo July-August 2011 25 (4) 687-690 UNIVERSITY OF STUDIES MESSINA SCHOOL OF MEDICINE AND SURGERY DEPARTMENT OF SURGERY, ONCOLOGY AND PATHOLOGY ANTONIO MACRÌ, EDOARDO SALADINO, GIUSEPPE TRIMARCHI, VINCENZO BARTOLO, MAURIZIO ROSSITTO, ANTONIO CANNAÒ, ANTONGIACOMO RIZZO, and CIRO FAMULARI
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients Vivo July-August 2011 25 (4) 687-690:
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients Vivo July-August 2011 25 (4) 687-690 UNIVERSITY OF STUDIES MESSINA SCHOOL OF MEDICINE AND SURGERY DEPARTMENT OF SURGERY, ONCOLOGY AND PATHOLOGY Copyright © 2011 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved